Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 8/20 | 0.84 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.59 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.54 |
| ▸ | PTGDR2 | Q9Y5Y4 | 7/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7066286 | 0.92 | AKR1B1 (0.83) | AKR1B1AKR1A1AKR1B10PTGDR2TDP1 | |
| SCHEMBL5466266 | 0.92 | AKR1B1 (1.00) | AKR1B1AKR1A1AKR1B10PTGDR2MAPT | |
| SCHEMBL7063354 | 0.89 | AKR1B1 (0.82) | AKR1B1AKR1A1AKR1B10PTGDR2 | |
| SCHEMBL5459444 | 0.88 | AKR1B1 (0.77) | AKR1B1AKR1A1AKR1B10PTGDR2 | |
| SCHEMBL7067035 | 0.87 | AKR1B1 (0.75) | AKR1B1AKR1A1AKR1B10PTGDR2 | |
| SCHEMBL5462608 | 0.87 | AKR1B1 (0.75) | AKR1B1AKR1A1AKR1B10PTGDR2TDP1 | |
| SCHEMBL7063287 | 0.87 | AKR1B1 (0.78) | AKR1B1AKR1A1AKR1B10PTGDR2 | |
| SCHEMBL7065032 | 0.86 | AKR1B1 (1.00) | AKR1B1AKR1A1AKR1B10PTGDR2MAPT | |
| SCHEMBL7064157 | 0.85 | AKR1B1 (0.72) | AKR1B1AKR1A1PTGDR2 | |
| SCHEMBL5466063 | 0.85 | AKR1B1 (0.72) | AKR1B1AKR1A1PTGDR2MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030036558-A1 | Substituted phenoxyacetic acids | THE INSTITUTES OF PHARMACEUTICAL DISCOVERY LLC. | 2003-02-20 | — | — | US | claimed |
| JP-2003503381-A | — | — | 2003-01-28 | — | — | JP | claimed |
| US-6420426-B1 | USED TO TREAT COMPLICATIONS FROM DIABETES MELLITUS | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY LLC | 2002-07-16 | — | — | US | claimed |
| EP-1198451-A2 | SUBSTITUTED PHENOXYACETIC ACIDS | The Institutes for Pharmaceutical Discovery, LLC (US) | 2002-04-24 | — | — | EP | claimed |
| WO-2001000566-A2 | SUBSTITUTED PHENOXYACETIC ACIDS | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2001-01-04 | — | — | WO | claimed |
| US-20070161631-A1 | Substituted Phenoxyacetic Acids | PHARMACIA & UPJOHN COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070161631-A1 | Substituted Phenoxyacetic Acids | PHARMACIA & UPJOHN COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-7189749-B2 | Substituted phenoxyacetic acids | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY LLC (US) | 2007-03-13 | — | — | US | disclosed |
| US-7189749-B2 | Substituted phenoxyacetic acids | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY LLC (US) | 2007-03-13 | — | — | US | disclosed |
| US-20030036558-A1 | Substituted phenoxyacetic acids | THE INSTITUTES OF PHARMACEUTICAL DISCOVERY LLC. | 2003-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161631-A1 | Substituted Phenoxyacetic Acids | SLC5A2, GPR119, SLC5A1 | AKR1B1 708/4885AKR1A1 791/4885AKR1B10 1623/4885 |
| US-20030036558-A1 | Substituted phenoxyacetic acids | SLC5A2, GPR119, SLC5A1 | AKR1B1 708/4885AKR1A1 791/4885AKR1B10 1623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.